English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Tuesday, December 2, 2025
君聖泰醫藥公佈HTD1801與達格列淨的頭對頭III期臨床研究結果 展現控糖優勢及心血管代謝優效獲益
君圣泰医药公布HTD1801与达格列净的头对头III期临床研究结果 展现控糖优势及心血管代谢优效获益
Friday, October 31, 2025
HTD1801, a First-in-Class Anti-inflammatory Metabolic Modulator, Demonstrates Durable 52-Week Efficacy and Safety in Two Phase III Trials in Type 2 Diabetes Mellitus
全球首創抗炎代謝調節劑HTD1801完成2型糖尿病III期臨床研究 展現持續52周的綜合獲益與安全性優勢
???????????HTD1801??2????III????? ????52????????????
Tuesday, September 23, 2025
心肾代谢综合征(CKM)治疗的新范式 君圣泰的"一药多效"迎来价值重估
Wednesday, September 17, 2025
EASD 2025 | 君聖泰醫藥口頭報告HTD1801治療2型糖尿病臨床3期研究成果
EASD 2025 | HighTide Therapeutics Announces Oral Presentation of Phase 3 Data in Patients with Type 2 Diabetes
EASD 2025 | 君圣泰医药口头报告HTD1801治疗2型糖尿病临床3期研究成果
Thursday, April 24, 2025
HighTide Therapeutics to Showcase New Analyses of Phase 2 MASH/T2DM Studies of Berberine Ursodeoxycholate (HTD1801) and Pre-Clinical Results of Rimtoregtide (HTD4010) in Presentations at EASL Congress 2025

Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575